comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-05 06:07:07 - browse：5957

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How to fix the rural physician shortage in the U.S.

leisure time

WSS

Chan Zuckerberg Biohub Chicago to focus on inflammation

Clinical trials giant ICON acquires HumanFirst

Colorectal cancer study finds potential in overlooked immune cell

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Biotech companies concerned about China biosecurity crackdown

Stroke deaths set to near 10 million globally by 2050

explore

comprehensive

explore

Moonlake's readout produced a cash windfall. Risks remain

Bristol 'take

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Walensky prepares to leave CDC — and Congress — behind

Medical device lobby: We're tired of waiting on Medicare coverage

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In search for therapies for solid tumors, companies turn to claudin

Supreme Court strikes down use of affirmative action

ALS groups 'won't be played again' by the FDA, drug sponsors

knowledge

Bristol 'take

What to expect at HLTH 2023, the health care industry conference

Flu vaccine offering decent levels of protection this winter, new data show

Analysis of telehealth claims data suggest service duplication

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Pfizer highlights cancer drugs it thinks could reignite investor interest

focus

leisure time

leisure time

leisure time